Efficacy and tolerance of interferon-α2b in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment

Campistol, Josep M.; Esforzado, Núria; Martínez, Joaquim; Roselló, Lluís; Veciana, Lluís; Mòdol, Josep María; Casellas, Joan; Pons, Mercé; Cuevas, X; Piera, J.F. Navarro; Oliva, J A; Costa, Josep; Barrera, J.M.; Bruguera, Miquel

doi:10.1093/ndt/14.11.2704

Cited by 101 publications

(56 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The relationship between immunosuppression and worsening of clinical disease in hepatitis C is well known (23). Various regimens, including interferon, have been attempted in the peritransplant course, with mixed results (24)(25)(26)(27)(28)(29). These studies also suggest that interferon treatment, especially after transplantation, may stimulate the immune system and lead to allograft rejection.…”

Section: Discussionmentioning

confidence: 99%

Hepatitis C Virus Seropositivity at the Time of Renal Transplantation in the United States: Associated Factors and Patient Survival

Batty¹,

Swanson²,

Kirk³

et al. 2001

Am J Transplant

View full text Add to dashboard Cite

National statistics for patient characteristics and survival of renal transplant recipients positive for hepatitis C virus (HCVπ 01 by log rank test). In Cox regression, mortality was higher for HCVπ (adjusted hazard ratio Ω 1.23, 95% confidence interval Ω 1.01-1.49, p Ω0.04). HCVπ recipients were more likely to be African-American, male, older, and to have received repeat transplants and donor HCVπ transplants. HCVπ recipients also had substantially longer waiting times for transplant. In contrast to recent studies, diabetes did not have an increased association with HCVπ , perhapsThe opinions are solely those of the authors and do not represent an endorsement by the Department of Defense. 179due to limitations of the database. HCVπ recipients had increased mortality and hospitalization rates compared with other transplant recipients.

show abstract

Section: Discussionmentioning

confidence: 99%

Hepatitis C Virus Seropositivity at the Time of Renal Transplantation in the United States: Associated Factors and Patient Survival

Batty¹,

Swanson²,

Kirk³

et al. 2001

Am J Transplant

View full text Add to dashboard Cite

show abstract

“…In the majority of trials interferon was administered subcutaneously; in one study it was given by an intramuscular route. 44 Two (14.3%) studies were randomized clinical trials 41,48 while the others were prospective, cohort studies.…”

Section: Clinical Trialsmentioning

confidence: 99%

“…In other words, these studies may not be measuring the same underlying quantity from the same base population. The summary estimates may not Chan TM, et al [43] Campistol J.M, et al [48] Hanrotel C, et al [52] Espinosa M, et al [49] Huraib S, et al [51] Fernandez J.L, et al [41] Mean overall estimate Koenig P, et al [33] Izopet J, et al [42] Casanovas-Taltavull T, et al…”

Section: Heterogeneity Analysismentioning

confidence: 99%

“…Uchihara M, et al [44] Benci A, et al [45] Chan T.M, et al [43] Izopet J, et al [42] Campistol J.M, et al [48] Hanrotel C, et al [52] Espinosa M, et al [49] Fernandez J.L, et al [41] Huraib S, et al [51] Mean overall estimate Koenig P, et al [33] Casanovas-Taltavull T, et al [50] Raptopoulou-Gigi M, et al [39] Pol S, et al [38] Degos F, et al [53] Patients discontinued treatment (%) -10% 10% 20% 30% 40% 50% 60% 70% 80% 90% 0% be the best descriptive analysis, since they assume that all estimates from individual studies are from the same population. The sources of between study heterogeneity are unclear.…”

Section: Heterogeneity Analysismentioning

confidence: 99%

See 1 more Smart Citation

Meta‐analysis: interferon for the treatment of chronic hepatitis C in dialysis patients

Fabrizi

Dulai²,

Dixit

et al. 2003

Aliment Pharmacol Ther

145

129

View full text Add to dashboard Cite

SUMMARYBackground: The efficacy of interferon monotherapy in dialysis patients with chronic hepatitis C remains unclear, although a number of small clinical trials have been published addressing this issue. Methods and aims: We evaluated the efficacy and safety of initial interferon monotherapy in dialysis patients with chronic hepatitis C by performing a systematic review of the literature with a meta-analysis of clinical trials. The primary outcome was sustained virological response (as a measure of efficacy); the secondary outcome was drop-out rate (as a measure of tolerability). We used the random effects model of Der Simonian and Laird, with heterogeneity and sensitivity analyses. Results: We have identified 14 clinical trials (269 unique patients); two were controlled studies. The mean overall estimate for sustained virological response (SVR) and drop-out rate was 37% [95% confidence interval (CI) 28-48] and 17% (95% CI 10-28),

show abstract

“…Twenty studies met inclusion criteria ( Figure 1) with individual patient data published in 13 studies (27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39) and obtained for three additional studies after contacting authors (40 -42). Limited data based on inclusion criteria were imputed for the remaining four studies (43)(44)(45)(46), but no further data were provided despite multiple attempts to contact authors.…”

Section: Study Characteristicsmentioning

confidence: 99%

Interferon for Hepatitis C Virus in Hemodialysis—an Individual Patient Meta-analysis of Factors Associated with Sustained Virological Response

Gordon¹,

Uhlig²,

Lau

et al. 2009

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Background and objectives: Hepatitis C virus (HCV) infection is prevalent in hemodialysis patientsResults: Twenty studies of IFN treatment provided data on 428 patients. Overall SVR was 45% and in univariate analyses was higher with: 1) three million units or higher three times weekly of IFN; 2) treatment for at least 6 mo; 3) treatment completion; 4) lower baseline HCV RNA; 5) female gender; and 6) early virological negativity. Although limited by missing data, these relationships persisted in multivariate regression.Conclusions: SVR is more likely with larger IFN dose, longer treatment duration, treatment completion, female gender, lower HCV RNA and early virological negativity. For appropriate treatment candidates, regimens should consist of three million units of IFN three times weekly for at least 6 mo, with patients encouraged to complete the full course.

show abstract

Efficacy and tolerance of interferon-α2b in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment

Cited by 101 publications

References 31 publications

Hepatitis C Virus Seropositivity at the Time of Renal Transplantation in the United States: Associated Factors and Patient Survival

Hepatitis C Virus Seropositivity at the Time of Renal Transplantation in the United States: Associated Factors and Patient Survival

Meta‐analysis: interferon for the treatment of chronic hepatitis C in dialysis patients

Interferon for Hepatitis C Virus in Hemodialysis—an Individual Patient Meta-analysis of Factors Associated with Sustained Virological Response

Contact Info

Product

Resources

About